Institutional members access full text with Ovid®

Share this article on:

Cardiac Biointerventions: Whatever Happened to Stem Cell and Gene Therapy?

Rosengart, Todd K. MD*†; Fallon, Eleanor BS; Crystal, Ronald G. MD

Innovations:Technology and Techniques in Cardiothoracic and Vascular Surgery: May/June 2012 - Volume 7 - Issue 3 - p 173–179
doi: 10.1097/IMI.0b013e318265d9f6
Review Article

Angiogenic gene therapy and stem cell administration represent two “biologic” interventions for the treatment of cardiac disease that were first introduced more than 15 years ago but still have not achieved approval for clinical use for the treatment of myocardial ischemia and heart failure. Challenges that have been encountered in the clinical testing of these new treatment strategies have included a lack of placebo controls in phase I surgical trials and the incorporation of potentially ineffectual agent delivery via intracoronary routes. Although enthusiasm for these approaches may therefore have ebbed, new refinements in these technologies and insights into their appropriate clinical testing suggest that a resurgence of interest in these “biointerventions” may be expected in the near future.

From the *Division of Cardiothoracic Surgery, Department of Surgery, †Stony Brook University Medical Center, Stony Brook, NY USA; and ‡Department of Genetic Medicine, Weill Cornell Medical College, New York, NY USA.

Accepted for publication June 20, 2012.

Presented at the Annual Scientific Meeting of the 21st Century Cardiothoracic Surgical Society, February 17–19, 2012, Boca Raton, FL USA.

Disclosure: The authors declare no conflict of interest.

Address correspondence and reprint requests to Todd K. Rosengart, MD, Division of Cardiothoracic Surgery, Department of Surgery, Stony Brook University Medical Center, Health Sciences Center T19-020, Stony Brook, NY 11794-8020 USA. E-mail:

Copyright © 2012 by the International Society for Minimally Invasive Cardiothoracic Surgery. Unauthorized reproduction of this article is prohibited.